Ohr Pharmaceutical Inc (OHRP): Jason Scott Slakter , CEO of Ohr Pharmaceutical Inc purchased 6,250 shares on Apr 11, 2016. The Insider buying transaction was disclosed on Apr 12, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.35 per share for a total value of $20,937.50.
Currently the company Insiders own 17.7% of OHR Pharmaceutical Inc shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by 2.61%.Institutional Investors own 11.73% of OHR Pharmaceutical Inc shares.During last six month period, the net percent change held by insiders has seen a change of 1335.69%.
Shares of OHR Pharmaceutical Inc (OHRP) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -0.1 points or -2.99% at $3.25 with 2,46,226 shares getting traded. Post opening the session at $3.4, the shares hit an intraday low of $3.19 and an intraday high of $3.4 and the price vacillated in this range throughout the day. The company has a market cap of $102 M and the number of outstanding shares has been calculated to be 3,14,61,869 shares. The 52-week high of OHR Pharmaceutical Inc is $6.56 and the 52-week low is $2.02.
Ohr Pharmaceutical Inc. is a pharmaceutical company. The Company is focusing on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company’s development pipeline consists of various programs and indications at various stages of development. The Company’s clinical program OHR-102 eye drops is a therapeutic product that provides a non-invasive therapy to improve vision outcomes without requiring multiple injections per office visit. The Company focuses on OHR-102 eye drops which is given in combination with Lucentis injections for the treatment of retinal diseases including wet-age-related macular degeneration (AMD) retinal vein occlusion and proliferative diabetic retinopathy. The Company’s product pipeline also includes SKS Sustained Release Ocular Drug Delivery Platform Technology Animal Model for Dry-AMD and Non-Ophthalmology Assets. OHR-102 is a small molecule anti-angiogenic drug with an intracellular mechanism of action.